» Articles » PMID: 33666785

Identify Potential MiRNA-mRNA Regulatory Networks Contributing to High-risk Neuroblastoma

Overview
Publisher Springer
Specialty Oncology
Date 2021 Mar 5
PMID 33666785
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroblastoma (NB) is a common tumor in children, usually in the retroperitoneum. After various treatments, low- and intermediate-risk patients have achieved good results, but the prognosis of high-risk patients is still very poor. Therefore, it is necessary to find new effective targets for the treatment of high-risk patients. In this study, comprehensive bioinformatics analysis was used to identify the differentially expressed genes (DEG and DEM) between high-risk patients and non-high-risk patients, and it was identified that ADRB2 may affect the survival status of high-risk patients due to miR -30a-5p regulation. The GSE49710, GSE73517, and GSE121513 datasets were downloaded from the Gene Expression Synthesis (GEO) database, and DEG and DEM were selected. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were applied to the selected DEGs. The STRING database and Cytoscape software were used to construct protein-protein interaction (PPI) networks and perform modular analysis of the DEGs. The TARGET data set containing information on overall survival days were used for the prognostic analysis of central genes. We identified a total of 255 DEGs from GSE49710 and GSE73517, and 193 DEMs from GSE121513. We identified the 5 most important central genes from the PPI network, performed a prognostic analysis in the target data set, and verified their expression using RT-qPCR to select the most important ADRB2 gene to predict miRNA. Integrating the differential miRNA predicted by miRDB and miRSystem and GSE121513 between the targeted miRNA and the prognosis, miR-30a-5p was finally identified as the targeted miRNA of ADRB2.

Citing Articles

Comprehensive analysis of lipid metabolic signatures identified CEBPD promotes breast cancer cell proliferation.

Zhao Y, He H, Huang L, Yu L Sci Rep. 2025; 15(1):6570.

PMID: 39994306 PMC: 11850814. DOI: 10.1038/s41598-025-90869-5.


Comprehensive analysis reveals the tumor suppressor role of macrophage signature gene FCER1G in hepatocellular carcinoma.

Kong D, Zhang Y, Jiang L, Long N, Wang C, Qiu M Sci Rep. 2025; 15(1):3995.

PMID: 39893200 PMC: 11787346. DOI: 10.1038/s41598-025-88071-8.


Comprehensive analysis identifies ubiquitin ligase FBXO42 as a tumor-promoting factor in neuroblastoma.

Zhou J, Li Q, Deng X, Peng L, Sun J, Zhang Y Sci Rep. 2024; 14(1):18697.

PMID: 39134694 PMC: 11319589. DOI: 10.1038/s41598-024-69760-2.


miRNA326-5p Targets DKC1 Gene to Regulate Apoptosis-Related Proteins and Intervene in the Development of Neuroblastoma.

Wang X, Zhang S, Wu H, Gao J, Wang L, Wang X Anal Cell Pathol (Amst). 2023; 2023:6761894.

PMID: 37426487 PMC: 10329557. DOI: 10.1155/2023/6761894.


Expression of ADRB2 in children with neuroblastoma and its influence on prognosis.

Cao L, Liu Q, Ma Y, Shao F, Zhao Z, Deng X Front Surg. 2022; 9:1026156.

PMID: 36406346 PMC: 9666690. DOI: 10.3389/fsurg.2022.1026156.

References
1.
Kholodenko I, Kalinovsky D, Doronin I, Deyev S, Kholodenko R . Neuroblastoma Origin and Therapeutic Targets for Immunotherapy. J Immunol Res. 2018; 2018:7394268. PMC: 6079467. DOI: 10.1155/2018/7394268. View

2.
Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View

3.
Fonseka P, Liem M, Ozcitti C, Adda C, Ang C, Mathivanan S . Exosomes from N-Myc amplified neuroblastoma cells induce migration and confer chemoresistance to non-N-Myc amplified cells: implications of intra-tumour heterogeneity. J Extracell Vesicles. 2019; 8(1):1597614. PMC: 6461098. DOI: 10.1080/20013078.2019.1597614. View

4.
Koneru B, Lopez G, Farooqi A, Conkrite K, Nguyen T, Macha S . Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Res. 2020; 80(12):2663-2675. PMC: 7313726. DOI: 10.1158/0008-5472.CAN-19-3068. View

5.
Strother D, London W, Schmidt M, Brodeur G, Shimada H, Thorner P . Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012; 30(15):1842-8. PMC: 3383182. DOI: 10.1200/JCO.2011.37.9990. View